Site tools

Print this page Email this page

Text size – +

You are here: Home > Governance > Executive management

Timothy Wright BSc PhD MBA

Commercial Director

Dr Tim Wright, 50, joined Vectura as Commercial Director in March 2005. Prior to joining Vectura he gained a breadth of experience in business development and licensing in a number of senior roles at BTG plc, latterly as Vice President Business Development and Licensing, Oncology, and as Director of Business Development at DevCo Pharmaceuticals, where he was successful in building a portfolio of neuroscience development candidates. Between 1986 and 1999 Tim held a number of management positions at GlaxoWellcome Research and Development, both in Clinical Pharmacology and Medical Operations, and in project management at Simbec Research Limited. Tim trained as a research scientist at London University, obtaining a PhD in neuroendocrinology in 1987. He was awarded an MBA from London Business School’s Executive Programme in 1994.

Martin John Shott PhD

Pharmaceutical Operations Director

Dr Martin Shott, 59 joined Vectura as Pharmaceutical Operations Director in October 2002 with a wide range of experience from within the pharmaceutical industry. Prior to joining Vectura he worked for four years at Innovata Biomed as Associate Director of Research and Development. Martin has gained extensive experience in the UK and Europe working as a senior manager at several companies, including Lers-Synthelabo and Ciba-Geigy (later Novartis), where he managed the global DPI development unit based in the UK. He trained as a research scientist, during which time he investigated the compression of pharmaceutical powders for a PhD at Nottingham University, while continuing to work in the industry.

Mark Jonathan Main BSc PhD

Development Director

Dr Mark Main, 51, joined Vectura as Development Director in May 2004. Prior to joining Vectura he was with Powderject Pharmaceuticals, which he joined in 2001 to lead multi-disciplinary development teams for both drug delivery and vaccine products involving all aspects of the drug/device development process. He was previously with Sterling Winthrop in 1986 and subsequently Parke-Davis, Ipsen International, and Scotia Pharmaceuticals, gaining extensive experience of clinical development and project management in the areas of cardiovascular and oncological treatment. Mark trained as a research scientist at St George’s Hospital Medical School, where he gained his doctorate investigating the prevention of ischaemiainduced damage of the mammalian myocardium.

 

Stephen William Eason BSc (Eng)

Director of Device Development

Stephen Eason, 53, joined Vectura in 2002 as Director of Device Development. He has overall responsibility for the development of Vectura’s inhaler technologies and leads a team of device engineers and designers based in Cambridge. Stephen joined Vectura from Cambridge Consultants Limited (CCL), where in 1999 he had set up and led CCL’s Drug Delivery Devices Group. The team carried out significant product developments in the areas of inhalation, injection and infusion products. Before specialising in drug delivery, Stephen managed a number of healthcare, telecoms and consumer product developments for clients in Europe and the US. Prior to joining CCL, Stephen worked in design and development for Baxter Healthcare. He studied Mechanical Engineering at the Imperial College of Science and Technology, London.

Colin Clive Dalton BTech PhD

Director of Intellectual Property and Corporate Affairs

Dr Colin Dalton, 61, joined Vectura as Director of IP and Corporate Affairs in January 2007 when Innovata plc was acquired. He was previously Corporate Development Director with Innovata and Quadrant Healthcare Limited, a formulation company acquired by Innovata. For five years prior to joining Quadrant he was Director of Business Development at GSK Biologicals where he managed a group responsible for licensing new products and technologies, collaborations and alliances. He previously worked in business development at Quadrant and British Sugar plc and was a senior consultant in the biotechnology practice at PA Consulting. He started his career as a fermentation scientist at BP Co Ltd. He trained as an applied biologist at Brunel University and obtained a PhD in 1977 at Leicester University.

Trevor Phillips BSc PhD MBA

President of US Operations

Dr Trevor Phillips, 50, joined Vectura as President of US operations in January 2010. Prior to joining Vectura he gained extensive international experience in organisational leadership, management and pharmaceutical drug development in a number of senior roles, including positions as CEO and President of the US publicly held company, Critical Therapeutics Inc, following six years as the Company’s Chief Operating Officer. During his time at Critical, Trevor was involved in setting up commercial partnerships, programme in-licensing and out-licensing, managing drug development, including NDA filings, manufacturing and mergers and acquisitions. Between 1986 and 2002 Trevor held a number of management positions at Sepracor, Scotia Pharmaceuticals, Accenture, GlaxoWellcome Research and Development and Simbec Research Limited. Trevor trained as a research scientist at University of Reading, obtaining a PhD in microbial biochemistry from the University of Wales in 1986. He was awarded an MBA from Henley Management College in 1997.